News Sentiment

ALKS sentiment intelligence

Alkermes Plc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 51.94 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 64

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-4.8% over one week, +17.3% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes (ALKS)

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -4.8% Price reacting lower
Trend fit Trend active 17.3% over four weeks
Fair value 74.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 37
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 64
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
simplywall.st 7
Stock Titan 7
Market source 6
Investing.com 4
Business Wire 3
GuruFocus 3
MSN 3
marketscreener.com 3

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 19
Deals and strategy 5
Analyst action 3
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
Sahm Direct company coverage

Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study

Alkermes plc (NASDAQ: ALKS) announced positive interim results from its long-term extension study of alixorexton, showing sustained improvements in wakefulness, daytime sleepiness, cognition, and fatigue for adults with narcolepsy type 1 and 2. Participants in both groups demonst

Tone
Positive 74/100
Event
Earnings
Published
14 Jul 2026 13:40
Source
Sahm
TradingView Direct company coverage

Enterprise value to EBIT forward of Alkermes plc – NASDAQ:ALKS

This article focuses on the enterprise value to EBIT forward for Alkermes plc (NASDAQ: ALKS). It appears to be a financial data point or analysis page from TradingView, providing an overview of this specific financial metric for the pharmaceutical company.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 16:40
Source
TradingView
TradingKey Direct company coverage

Alkermes Plc (ALKS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Alkermes Plc (ALKS) by business segment and by region, with data current as of April 6. The report highlights key product contributions such as VIVITROL, ARISTADA, and LYBALVI, which together account for a significant portion

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:40
Source
TradingKey
Stock Titan Direct company coverage

Alkermes (ALKS) director sells 2,000 shares under Rule 10b5-1 plan

Alkermes plc director Christopher I. Wright reported an open-market sale of 2,000 Ordinary Shares at $45.10 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026. Following this transaction, Wright directly holds 25,680 Ordinary Shares. The sale amount

Tone
Negative 38/100
Event
Market update
Published
13 Jun 2026 00:18
Source
Stock Titan
GuruFocus Direct company coverage

Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tells Investors

Alkermes PLC (ALKS) shares surged 4.4% to $44.28 on June 9, 2026, driven by strong momentum despite being identified as significantly overvalued by GuruFocus's GF Value™ methodology. The company holds an above-average GF Score™ of 74/100, though its financial strength and profita

Tone
Negative 39/100
Event
Market update
Published
10 Jun 2026 00:39
Source
GuruFocus
Stock Titan Direct company coverage

Alkermes (ALKS) EVP Gaffin sells 2,034 shares under 10b5-1 plan

David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes plc (ALKS), reported an open-market sale of 2,034 Ordinary Shares at an average price of $43.05 per share on June 4, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November

Tone
Negative 39/100
Event
Market update
Published
04 Jun 2026 21:00
Source
Stock Titan
Market source Direct company coverage

Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?

Alkermes (ALKS) has seen its shares increase by 21.1% since its last earnings report, outperforming the S&P 500. The company reported a narrower-than-expected Q1 2026 loss and beat revenue estimates, driven by strong sales of its proprietary products like Vivitrol, Aristada, Lyba

Tone
Neutral 50/100
Event
Earnings
Published
04 Jun 2026 15:30
Source
Market source
MSN Direct company coverage

Alkermes to participate in the Goldman Sachs 47th annual global healthcare conference

Alkermes plc (ALKS) announced its participation in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference. The company's management will present at the conference on June 11, 2026, at 9:20 a.m. ET. A live webcast of the presentation will be available on the Alkermes

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 01:09
Source
MSN
Business Wire Direct company coverage

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

Alkermes plc announced it will present 11 posters at the American Society of Clinical Psychopharmacology Annual Meeting. The presentations will feature clinical and real-world data from their psychiatry and orexin portfolios, including commercial medicines LYBALVI and ARISTADA, a

Tone
Positive 66/100
Event
Market update
Published
27 May 2026 08:09
Source
Business Wire